Skip to content

Ocular Therapeutix OCUL Other Commercial Liabilities

Other Commercial Liabilities at other companies

Bausch + Lomb logo
Bausch + LombBLCO
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Glaukos logo
GlaukosGKOS
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's other commercial liabilities?
Ocular Therapeutix (OCUL) reported other commercial liabilities of $36.49M in Q1 2026.
How has Ocular Therapeutix's other commercial liabilities changed year-over-year?
Ocular Therapeutix's other commercial liabilities increased by 17.4% year-over-year, from $31.08M to $36.49M.
What is the long-term trend for Ocular Therapeutix's other commercial liabilities?
Over 5 years (2020 to 2025), Ocular Therapeutix's other commercial liabilities has grown at a 25.1% compound annual growth rate (CAGR), from $14.31M to $43.84M.